Efficacy of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors in the Treatment of Chronic Heart Failure: A Review of Landmark Trials
Heart failure (HF) is a multi-faceted clinical condition affecting up to 2% of the population in the developed world and is linked to significant morbidity and mortality, therefore posing a major public health concern. To this date, pharmacotherapy for HF has mainly focused on chronic HF with reduce...
Gespeichert in:
Veröffentlicht in: | Curēus (Palo Alto, CA) CA), 2019-01, Vol.11 (1), p.e3913 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 1 |
container_start_page | e3913 |
container_title | Curēus (Palo Alto, CA) |
container_volume | 11 |
creator | Bratsos, Sosipatros |
description | Heart failure (HF) is a multi-faceted clinical condition affecting up to 2% of the population in the developed world and is linked to significant morbidity and mortality, therefore posing a major public health concern. To this date, pharmacotherapy for HF has mainly focused on chronic HF with reduced ejection fraction (HFrEF), with angiotensin converting enzyme inhibitors (ACEi) being at the centre of the management plan, alongside angiotensin-receptor-blockers (ARBs), β-blockers (BB) and mineralocorticoid receptor antagonists (MRAs). A novel and recently approved therapy, however, involving angiotensin receptor-neprilysin inhibitors (ARNI), has shown very promising results and comparable to those of ACEi, which raises the question of whether ACEi should remain the first-line treatment option for HFrEF. In this review, the evidence regarding the clinical efficacy of ACEi and ARNI in the treatment of HFrEF is discussed, with emphasis placed on the major landmark trials. |
doi_str_mv | 10.7759/cureus.3913 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6426571</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2200579521</sourcerecordid><originalsourceid>FETCH-LOGICAL-c339t-b50617a73138a22df9caee8481b0a11fda12f3fcdc03ed8eb32cb56c81a82c243</originalsourceid><addsrcrecordid>eNpdkk1rGzEQhkVpSUKaU-5F0EuhbKoP7662h4IxThMwCZT0LLTaka10V3IlrYv7k_orq8VpcHoaaebRO--gQeiSkqu6LptPegwwxiveUP4KnTFaiUJQMXt9dD5FFzE-EkIoqRmpyQk65aThNJfO0J-lMVYrvcfe4LlbW5_ARevwwrsdhGTdGi_d7_0A-NZtbGuTDxEr172Av4GGba4Ud7ANtt9PuSM839IG8EMAlQZwaeq12ATvrMY3oELC18r2eZLPeJ61dhZ-TcgqtxlU-JEfWtXHt-iNyQEunuI5-n69fFjcFKv7r7eL-arQnDepaEtS0VrVnHKhGOtMoxWAmAnaEkWp6RRlhhvdacKhE9Byptuy0oIqwTSb8XP05aC7HdsBOp0NB9XLPFg2s5deWfmy4uxGrv1OVjNWlTXNAh-eBIL_OUJMcrBRQ98rB36MkjFCayqIaDL6_j_00Y_B5fEmipR1U7JJ8OOB0sHHGMA8m6FETmsgD2sgpzXI9Ltj_8_sv0_nfwGcm7MZ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2200579521</pqid></control><display><type>article</type><title>Efficacy of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors in the Treatment of Chronic Heart Failure: A Review of Landmark Trials</title><source>PubMed Central Free</source><source>PubMed Central Open Access</source><creator>Bratsos, Sosipatros</creator><creatorcontrib>Bratsos, Sosipatros</creatorcontrib><description>Heart failure (HF) is a multi-faceted clinical condition affecting up to 2% of the population in the developed world and is linked to significant morbidity and mortality, therefore posing a major public health concern. To this date, pharmacotherapy for HF has mainly focused on chronic HF with reduced ejection fraction (HFrEF), with angiotensin converting enzyme inhibitors (ACEi) being at the centre of the management plan, alongside angiotensin-receptor-blockers (ARBs), β-blockers (BB) and mineralocorticoid receptor antagonists (MRAs). A novel and recently approved therapy, however, involving angiotensin receptor-neprilysin inhibitors (ARNI), has shown very promising results and comparable to those of ACEi, which raises the question of whether ACEi should remain the first-line treatment option for HFrEF. In this review, the evidence regarding the clinical efficacy of ACEi and ARNI in the treatment of HFrEF is discussed, with emphasis placed on the major landmark trials.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.3913</identifier><identifier>PMID: 30931184</identifier><language>eng</language><publisher>United States: Cureus Inc</publisher><subject>Blood pressure ; Cardiology ; Classification ; Drug dosages ; Dyspnea ; Ejection fraction ; Enzymes ; Heart failure ; Internal Medicine ; Medical prognosis ; Mortality ; Peptides ; Public health</subject><ispartof>Curēus (Palo Alto, CA), 2019-01, Vol.11 (1), p.e3913</ispartof><rights>Copyright © 2019, Bratsos et al. This work is published under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2019, Bratsos et al. 2019 Bratsos et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c339t-b50617a73138a22df9caee8481b0a11fda12f3fcdc03ed8eb32cb56c81a82c243</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426571/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426571/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30931184$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bratsos, Sosipatros</creatorcontrib><title>Efficacy of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors in the Treatment of Chronic Heart Failure: A Review of Landmark Trials</title><title>Curēus (Palo Alto, CA)</title><addtitle>Cureus</addtitle><description>Heart failure (HF) is a multi-faceted clinical condition affecting up to 2% of the population in the developed world and is linked to significant morbidity and mortality, therefore posing a major public health concern. To this date, pharmacotherapy for HF has mainly focused on chronic HF with reduced ejection fraction (HFrEF), with angiotensin converting enzyme inhibitors (ACEi) being at the centre of the management plan, alongside angiotensin-receptor-blockers (ARBs), β-blockers (BB) and mineralocorticoid receptor antagonists (MRAs). A novel and recently approved therapy, however, involving angiotensin receptor-neprilysin inhibitors (ARNI), has shown very promising results and comparable to those of ACEi, which raises the question of whether ACEi should remain the first-line treatment option for HFrEF. In this review, the evidence regarding the clinical efficacy of ACEi and ARNI in the treatment of HFrEF is discussed, with emphasis placed on the major landmark trials.</description><subject>Blood pressure</subject><subject>Cardiology</subject><subject>Classification</subject><subject>Drug dosages</subject><subject>Dyspnea</subject><subject>Ejection fraction</subject><subject>Enzymes</subject><subject>Heart failure</subject><subject>Internal Medicine</subject><subject>Medical prognosis</subject><subject>Mortality</subject><subject>Peptides</subject><subject>Public health</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkk1rGzEQhkVpSUKaU-5F0EuhbKoP7662h4IxThMwCZT0LLTaka10V3IlrYv7k_orq8VpcHoaaebRO--gQeiSkqu6LptPegwwxiveUP4KnTFaiUJQMXt9dD5FFzE-EkIoqRmpyQk65aThNJfO0J-lMVYrvcfe4LlbW5_ARevwwrsdhGTdGi_d7_0A-NZtbGuTDxEr172Av4GGba4Ud7ANtt9PuSM839IG8EMAlQZwaeq12ATvrMY3oELC18r2eZLPeJ61dhZ-TcgqtxlU-JEfWtXHt-iNyQEunuI5-n69fFjcFKv7r7eL-arQnDepaEtS0VrVnHKhGOtMoxWAmAnaEkWp6RRlhhvdacKhE9Byptuy0oIqwTSb8XP05aC7HdsBOp0NB9XLPFg2s5deWfmy4uxGrv1OVjNWlTXNAh-eBIL_OUJMcrBRQ98rB36MkjFCayqIaDL6_j_00Y_B5fEmipR1U7JJ8OOB0sHHGMA8m6FETmsgD2sgpzXI9Ltj_8_sv0_nfwGcm7MZ</recordid><startdate>20190119</startdate><enddate>20190119</enddate><creator>Bratsos, Sosipatros</creator><general>Cureus Inc</general><general>Cureus</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20190119</creationdate><title>Efficacy of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors in the Treatment of Chronic Heart Failure: A Review of Landmark Trials</title><author>Bratsos, Sosipatros</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c339t-b50617a73138a22df9caee8481b0a11fda12f3fcdc03ed8eb32cb56c81a82c243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Blood pressure</topic><topic>Cardiology</topic><topic>Classification</topic><topic>Drug dosages</topic><topic>Dyspnea</topic><topic>Ejection fraction</topic><topic>Enzymes</topic><topic>Heart failure</topic><topic>Internal Medicine</topic><topic>Medical prognosis</topic><topic>Mortality</topic><topic>Peptides</topic><topic>Public health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bratsos, Sosipatros</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bratsos, Sosipatros</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors in the Treatment of Chronic Heart Failure: A Review of Landmark Trials</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><addtitle>Cureus</addtitle><date>2019-01-19</date><risdate>2019</risdate><volume>11</volume><issue>1</issue><spage>e3913</spage><pages>e3913-</pages><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>Heart failure (HF) is a multi-faceted clinical condition affecting up to 2% of the population in the developed world and is linked to significant morbidity and mortality, therefore posing a major public health concern. To this date, pharmacotherapy for HF has mainly focused on chronic HF with reduced ejection fraction (HFrEF), with angiotensin converting enzyme inhibitors (ACEi) being at the centre of the management plan, alongside angiotensin-receptor-blockers (ARBs), β-blockers (BB) and mineralocorticoid receptor antagonists (MRAs). A novel and recently approved therapy, however, involving angiotensin receptor-neprilysin inhibitors (ARNI), has shown very promising results and comparable to those of ACEi, which raises the question of whether ACEi should remain the first-line treatment option for HFrEF. In this review, the evidence regarding the clinical efficacy of ACEi and ARNI in the treatment of HFrEF is discussed, with emphasis placed on the major landmark trials.</abstract><cop>United States</cop><pub>Cureus Inc</pub><pmid>30931184</pmid><doi>10.7759/cureus.3913</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2168-8184 |
ispartof | Curēus (Palo Alto, CA), 2019-01, Vol.11 (1), p.e3913 |
issn | 2168-8184 2168-8184 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6426571 |
source | PubMed Central Free; PubMed Central Open Access |
subjects | Blood pressure Cardiology Classification Drug dosages Dyspnea Ejection fraction Enzymes Heart failure Internal Medicine Medical prognosis Mortality Peptides Public health |
title | Efficacy of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors in the Treatment of Chronic Heart Failure: A Review of Landmark Trials |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T13%3A48%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20Angiotensin%20Converting%20Enzyme%20Inhibitors%20and%20Angiotensin%20Receptor-Neprilysin%20Inhibitors%20in%20the%20Treatment%20of%20Chronic%20Heart%20Failure:%20A%20Review%20of%20Landmark%20Trials&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Bratsos,%20Sosipatros&rft.date=2019-01-19&rft.volume=11&rft.issue=1&rft.spage=e3913&rft.pages=e3913-&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.3913&rft_dat=%3Cproquest_pubme%3E2200579521%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2200579521&rft_id=info:pmid/30931184&rfr_iscdi=true |